Robert Coffin Biography and Net Worth

Insider of Replimune Group

Robert Coffin is Founder, President and Chief Research & Development Officer of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013, before co-founding Replimune in 2015. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.

What is Robert Coffin's net worth?: The estimated net worth of Robert Coffin is at least $22.21 million as of May 16th, 2024. Dr. Coffin owns 1,821,872 shares of Replimune Group stock worth more than $22,208,620 as of November 13th. This net worth evaluation does not reflect any other assets that Dr. Coffin may own. Additionally, Dr. Coffin receives a salary of $785,890.00 as Insider at Replimune Group. Learn More about Robert Coffin's net worth.
How old is Robert Coffin?: Dr. Coffin is currently 59 years old. There are 9 older executives and no younger executives at Replimune Group. The oldest executive at Replimune Group is Dr. Colin A. Love Ph.D., Chief Operating Officer, who is 66 years old. Learn More on Robert Coffin's age.
What is Robert Coffin's salary?: As the Insider of Replimune Group, Inc., Dr. Coffin earns $785,890.00 per year. The highest earning executive at Replimune Group is Mr. Philip Astley-Sparke F.S.A., CEO & Director, who commands a salary of $1,070,000.00 per year. Learn More on Robert Coffin's salary.
How do I contact Robert Coffin?: The corporate mailing address for Dr. Coffin and other Replimune Group executives is 500 Unicorn Park, WOBURN MA, 01801. Replimune Group can also be reached via phone at (781) 222-9600 and via email at [email protected]. Learn More on Robert Coffin's contact information.
Has Robert Coffin been buying or selling shares of Replimune Group?: Robert Coffin has not been actively trading shares of Replimune Group within the last three months. Most recently, Robert Coffin sold 11,464 shares of the business's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a transaction totalling $74,172.08. Following the completion of the sale, the director now directly owns 1,821,872 shares of the company's stock, valued at $11,787,511.84. Learn More on Robert Coffin's trading history.
Who are Replimune Group's active insiders?: Replimune Group's insider roster includes Robert Coffin (Insider), Pamela Esposito (Insider), and Colin Love (COO). Learn More on Replimune Group's active insiders.
Are insiders buying or selling shares of Replimune Group?: During the last year, insiders at the sold shares 9 times. They sold a total of 123,849 shares worth more than $883,363.29. The most recent insider tranaction occured on August, 16th when CFO Emily Luisa Hill sold 8,938 shares worth more than $90,988.84. Insiders at Replimune Group own 8.8% of the company. Learn More about insider trades at Replimune Group.
Information on this page was last updated on 8/16/2024.

Robert Coffin Insider Trading History at Replimune Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/16/2024	Sell	11,464	$6.47	$74,172.08	1,821,872
7/2/2021	Sell	7,810	$40.04	$312,712.40
6/28/2021	Sell	14,663	$40.04	$587,106.52	1,806,320
1/22/2021	Sell	60,000	$44.43	$2,665,800.00	1,773,921
12/22/2020	Sell	220,000	$40.04	$8,808,800.00
7/9/2020	Sell	169,750	$22.13	$3,756,567.50	2,048,368
11/6/2019	Sell	48,500	$16.92	$820,620.00
10/31/2019	Sell	24,250	$17.02	$412,735.00
9/23/2019	Sell	24,250	$17.05	$413,462.50

Robert Coffin Buying and Selling Activity at Replimune Group

Replimune Group Company Overview

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Today's Range

Now: $12.19

$11.45

$12.60

50 Day Range

MA: $11.42

$10.34

$12.70

2 Week Range

Now: $12.19

$4.92

$12.97

Volume

460,407 shs

Average Volume

1,040,354 shs

Market Capitalization

$832.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

Robert Coffin Biography and Net Worth

What is Robert Coffin's net worth?

How old is Robert Coffin?

What is Robert Coffin's salary?

How do I contact Robert Coffin?

Has Robert Coffin been buying or selling shares of Replimune Group?

Who are Replimune Group's active insiders?

Are insiders buying or selling shares of Replimune Group?